Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec 15;71(12):3128-3135.
doi: 10.1093/cid/ciz1207.

Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections Among Patients With Neurogenic Bladder: A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections Among Patients With Neurogenic Bladder: A Randomized Controlled Trial

Aurélien Dinh et al. Clin Infect Dis. .

Abstract

Background: Recurrent urinary tract infections (R-UTIs) are the main cause of morbidity and hospitalizations in subjects with neurogenic bladder (NB) due to spinal cord injury (SCI). We evaluated the efficacy of weekly oral cyclic antibiotic (WOCA) prophylaxis (ie, the alternate weekly administration of 2 antibiotics) in preventing R-UTIs.

Methods: Randomized (1:1), open-label, superiority-controlled trial compared WOCA prophylaxis to no prophylaxis (control) for 6 months in patients with NB due to SCI, using clean intermittent self-catheterization, and suffering from R-UTIs. Primary outcome was incidence of symptomatic antibiotic-treated UTIs. Secondary outcomes were number of febrile UTIs, number of hospitalizations, WOCA tolerance, antibiotic consumption, number of negative urine cultures, and emergence of bacterial resistance in urinary, intestinal, and nasal microbiota.

Results: Forty-five patients were either allocated to the WOCA group (n = 23) or the control group (n = 22). Median (IQR) incidence of symptomatic antibiotic-treated UTIs was 1.0 (0.5-2.5) in the WOCA group versus 2.5 (1.2-4.0) (P = .0241) in the control group. No febrile UTIs were recorded in the WOCA group versus 9 (45.0%) (P < .001) in the control group. The median number of additional antibiotic treatment was 0.0 (IQR, 0.0-2.0) versus 3.0 (2.0-5.0) (P = .004) in the WOCA and control groups, respectively. Only few adverse events were reported. No impact on emergence of bacterial resistance was observed.

Conclusions: WOCA is efficient and well tolerated in preventing R-UTIs in SCI patients. In our study, we did not observe any emergence of antibiotic resistance in digestive and nasal microbiological cultures.

Clinical trials registration: NCT01388413.

Keywords: prophylaxis; UTI; multidrug-resistant organism; neurogenic bladder.

PubMed Disclaimer

Comment in

  • Letter to the Editor.
    Prabhakar NK, Mian M, Elliott CS. Prabhakar NK, et al. Clin Infect Dis. 2021 Oct 20;73(8):1549. doi: 10.1093/cid/ciab286. Clin Infect Dis. 2021. PMID: 33788921 No abstract available.
  • Reply to Author.
    Dinh A, Duran C, Bernard L. Dinh A, et al. Clin Infect Dis. 2021 Oct 20;73(8):1549-1550. doi: 10.1093/cid/ciab284. Clin Infect Dis. 2021. PMID: 33788934 No abstract available.
  • Infection and Inflammation of the Genitourinary Tract.
    Clemens JQ. Clemens JQ. J Urol. 2021 Nov;206(5):1306-1307. doi: 10.1097/JU.0000000000002157. Epub 2021 Aug 16. J Urol. 2021. PMID: 34392694 No abstract available.

Publication types

MeSH terms

Substances

Associated data